

(19)



Eur päisch s Patentamt

Europ an Pat nt Offic

Office ur pé n d s br vets



(11)

EP 1 219 638 A2

AS

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
03.07.2002 Bull tln 2002/27

(51) Int Cl.7: C07K 14/705, C12N 15/12

(21) Application number: 01310136.5

(22) Date of filing: 04.12.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 18.12.2000 GB 0308544
04.05.2001 GB 1110311

(83) Declaration under Rule 28(4) EPC (expert
solution)

(71) Applicants:
• Pfizer Limited
Sandwich, Kent CT13 9NJ (GB)
Designated Contracting States:
GB
• Pfizer Inc.
New York, New York 10017 (US)
Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR

(72) Inventor: Fldock, Mark David,
of Pfizer Global Research and
Sandwich, Kent CT13 9NJ (GB)

(74) Representative: Hayles, James Richard
UK Patent Department,
Pfizer Limited,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

Remarks:

The biological material has been deposited with
NCIMB Ltd., under number(s) NCIMB 41101

(54) G-protein coupled receptors having homology to the P2Y purinoreceptor 1 (P2Y1)

(57) Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 and variants, fragments, homo-

logues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof.

EP 1 219 638 A2

Description**Technical field**

- 5 [0001] The present invention relates to a novel polynucleotide sequence which encodes a novel polypeptide belonging to the class of proteins known as G-protein coupled receptors (GPCRs). The present invention also relates, inter alia, to processes for producing the polypeptide and its uses.

Background of the invention

10

[0002] Cells and tissues respond to a wide variety of extracellular signalling molecules through the interaction of these molecules with specific cell-surface receptors. One such class of receptors are known as G-protein coupled receptors (GPCRs) and these are characterised by containing a series of 7 hydrophobic transmembrane segments. Upon binding an extracellular ligand to its receptor, intracellular signals are initiated via interactions with heterotrimeric

15

G proteins which in turn can lead to a number of different intracellular events depending upon which receptor has been activated. For example some GPCRs influence adenylyl cyclase activity whereas others act via phospholipase C.

[0003] Members of the GPCR superfamily respond to a wide variety of ligands including small molecule amines (such as serotonin, dopamine, acetylcholine), purines and pyrimidines (such as ATP, ADP, adenosine, UTP, UDP), lipid-derived mediators (such as LPA), amino acid derivatives (such as glutamate) and neurotransmitter peptides and

20

hormones (such as neurokinin, galanin, glucagon, gastrin). Although GPCRs are activated by a broad range of ligands, it should be noted that individual GPCRs have a small and very specific repertoire of ligands. Based upon an analysis of the primary structure of a novel GPCR, it is now possible to classify them into specific sub-families, thereby narrowing the range of potential ligands.

25

[0004] In many cases, the endogenous ligands of GPCRs are relatively small, enabling them to be mimicked or blocked by synthetic analogues. For example drugs such as prazosin, doxazosin, cimetidine, ranitidine are all effective antagonists of their respective target GPCRs. Thus, as the activation or inhibition of GPCRs can have therapeutic consequences, there is a continued need to provide new GPCRs and their associated agonists and antagonists.

30

[0005] There are several diverse families of receptors which respond to purines and pyrimidines. Examples of members of the GPCR family of such receptors are the adenosine receptors designated A1, A2a, A2b, and A3; and several of the P2Y receptors which are stimulated by UDP, UTP, ADP, and ATP.

Summary of the invention

35

[0006] According to one aspect of the present invention, there is provided an isolated polynucleotide comprising:

40

- (a) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO: 2;
- (b) a polynucleotide encoding the polypeptide expressed by the DNA contained in National Collection of Industrial, Food and Marine Bacteria Limited (NCIMB) Deposit No. 41101;
- (c) a polynucleotide comprising a nucleotide sequence of SEQ ID NO 1;
- (d) a polynucleotide comprising a nucleotide sequence that has at least 70-75% identity to the polynucleotide of any one of (a) to (c);
- (e) a polynucleotide comprising a nucleotide sequence which is capable of hybridising to the polynucleotide of any one of (a) to (d); or
- (f) a polynucleotide fragment of the polynucleotide of any one of (a) to (e).

45

[0007] Preferably, the polynucleotide comprises a nucleotide sequence that has at least 75-80% identity to the polynucleotide of any one of (a) to (c) above. More preferably, the polynucleotide comprises a nucleotide sequence that has at least 80-85% identity to the polynucleotide of any one of (a) to (c) above. Even more preferably, the polynucleotide comprises a nucleotide sequence that has at least 85-90% identity to the polynucleotide of any one of (a) to (c) above.

50

Yet more preferably, the polynucleotide comprises a nucleotide sequence that has at least 90-95% identity to the polynucleotide of any one of (a) to (c) above. Most preferably, the polynucleotide comprises a nucleotide sequence that has greater than 95% identity to the polynucleotide of any one of (a) to (c) above.

[0008] Preferably, the polynucleotide encodes a mature polypeptide encoded by the DNA contained in NCIMB Deposit No. 41101.

55

[0009] The polynucleotide described above preferably encodes a G-protein coupled receptor (GPCR).

[0010] The present invention also provides a polynucleotide probe or primer comprising at least 15 contiguous nucleotides of the polynucleotide described above. The invention also provides antisense oligonucleotides which hybridise to the polynucleotide of SEQ ID NO 1 and allelic variants thereof and can be used to modify PFI-019 expression.

The invention also includes ribozymes which contain portions of sequence capable of hybridising to the polynucleotide of SEQ ID NO 1.

[0011] The present invention yet further provides a vector comprising the polynucleotide described above.

[0012] According to a further aspect of the present invention, there is provided a host cell transformed or transfected with the vector described above. Preferably, the host cell is a mammalian, bacterial or yeast cell.

[0013] According to yet a further aspect of the present invention, there is provided a process for producing a polypeptide or fragment thereof comprising culturing said host cell under conditions sufficient for the expression of said polypeptide or fragment. Preferably, said polypeptide or fragment is expressed at the surface of said cell. The process preferably further includes recovering the polypeptide or fragment from the culture.

[0014] There is also provided by the present invention a process for producing cells capable of expressing a polypeptide or fragment thereof comprising transforming or transfecting cells with the vector described above.

[0015] According to a further embodiment of the present invention, there are provided cells produced by the process described above. There is also provided a membrane preparation of said cells.

[0016] According to another aspect of the present invention, there is provided a polypeptide comprising:

(a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 and variants, fragments, homologues, analogues and derivatives thereof;

(b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof; or

(c) a polypeptide encoded by the cDNA of NCIMB Deposit No. 41101 and variants, fragments, homologues, analogues and derivatives of said polypeptide.

[0017] There is also provided by the present invention an antibody against the polypeptide described above.

[0018] The present invention yet further provides a compound which activates the polypeptide described above (an agonist) or which inhibits activation of the polypeptide described above (an antagonist). Preferably, such compounds are nucleotides or derivatives thereof.

[0019] According to another aspect of the invention, there is provided a method for identifying a compound which binds to the polypeptide of the invention, comprising:

(a) contacting (i) a detectable compound A, preferably a labelled derivative of a purinoceptor ligand known to bind to the polypeptide of the invention, more preferably a nucleotide derivative, even more preferably 2-chloro-ATP, 2-methyl-thio-ATP, or 2-methyl-thio-ADP, and (ii) a test compound (or mixture of test compounds), with cells expressing the polypeptide of the invention or a membrane preparation of such cells;

(b) contacting the same amount of detectable compound A with the same amount of cells expressing the polypeptide of the invention or a membrane preparation of such cells as in step (a) under the same conditions as in step

(a) but in the absence of test compound;

(c) comparing the amount of compound A bound in steps (a) and (b) thereby identifying a test compound (or mixture of test compounds) that competes with or blocks the binding of compound A to the polypeptide of the invention.

[0020] According to another aspect of the present invention, there is provided a method for identifying a compound which binds to and activates the polypeptide described above comprising:

(a) contacting a compound with cells expressing on the surface thereof the polypeptide or a membrane preparation of said cells, said polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said polypeptide; said contacting being under conditions sufficient to permit binding of compounds to the polypeptide; and

(b) identifying a compound capable of polypeptide binding by detecting the signal produced by said second component.

[0021] According to another aspect of the present invention, there is provided a method for identifying a compound which binds to and inhibits activation of the polypeptide described above comprising:

(a) contacting (i) a detectable first component known to bind to and activate the polypeptide and (ii) a compound with cells expressing on the surface thereof the polypeptide or a membrane preparation of said cells, said polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said polypeptide; said contacting being under conditions sufficient to permit binding of compounds to the polypeptide; and

(b) determining whether the first component binds to the polypeptide by detecting the absence or otherwise of a signal generated from the interaction of the first component with the polypeptide.

[0022] As GPCRs are involved in signal transduction, agonists or antagonists of the polypeptide of the present invention can find use in interfering in the signal transduction process. Consequently, the present invention provides a compound which activates the polypeptide described above (an agonist) or which inhibits activation of the polypeptide described above (an antagonist) for use as a pharmaceutical. Such compounds, which can act as agonists or antagonists of the polypeptide, can therefore find use in the therapeutic areas which concern aspects of signal transduction. Therapeutically useful areas include, but are not limited to, neurological disease, psychotherapeutics, urogenital disease, reproduction and sexual medicine, inflammation, cancer, tissue repair, dermatology, skin pigmentation, photo-ageing, frailty, osteoporosis, metabolic disease, cardiovascular disease, gastrointestinal disease, antiinfection, allergy and respiratory disease, sensory organ disorders, sleep disorders and hairloss. Preferably, therapeutically useful areas are hypertension, asthma, and atherosclerosis.

[0023] Accordingly, there is also provided the use of the above compound (agonist) in the manufacture of a medicament in the treatment of a patient having need to activate a receptor.

[0024] There is also provided the use of the above compound (antagonist) in the manufacture of a medicament in the treatment of a patient having need to inhibit a receptor.

[0025] According to yet a further aspect of the invention, there is provided a method for the treatment of a patient having need to activate a receptor comprising administering to the patient a therapeutically effective amount of the above-described compound (agonist). Preferably, said compound (agonist) is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said compound and expressing said compound *in vivo*.

[0026] According to yet a further aspect of the invention, there is also provided a method for the treatment of a patient having need to inhibit a receptor comprising administering to the patient a therapeutically effective amount of the above-described compound (antagonist). Preferably, said compound (antagonist) is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said compound and expressing said compound *in vivo*.

[0027] There is also provided by the present invention a method for the treatment of a patient having need to activate or inhibit a receptor, comprising administering to the patient a therapeutically effective amount of the antibody described above.

[0028] Yet further provided by the present invention is use of the antibody described above in the manufacture of a medicament for the treatment of a patient having need to activate or inhibit a receptor.

[0029] According to a further aspect of the present invention, there is provided a method of treatment of a patient having need to upregulate a receptor, comprising administering to the patient a therapeutically effective amount of the polypeptide of the present invention. Preferably, said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide *in vivo*.

[0030] There is also provided by the present invention, use of the polypeptide in the manufacture of a medicament for the treatment of a patient having need to upregulate a receptor.

[0031] According to yet a further aspect of the present invention, there are provided cells or an animal genetically engineered to overexpress, underexpress or to exhibit targeted deletion of the polypeptide of the present invention.

[0032] Another aspect of the invention is a method of elucidating the three-dimensional structure of the polypeptide of the invention, comprising the steps of: (a) purifying the polypeptide; (b) crystallising it, and (c) elucidating the structure, in particular by X-ray crystallography.

[0033] Yet a further embodiment of the invention is a method of modelling the structure of the polypeptide of the invention, comprising the steps of: (a) aligning the sequence with a sequence of a protein of known three-dimensional structure, in particular rhodopsin; (b) mapping the detected sequence differences of the polypeptide of the invention onto the known structure, (c) deriving a homology model of the polypeptide of the invention.

Detailed description of the invention

[0034] The polynucleotide which encodes the GPCR of the present invention was identified electronically and analysed using various bioinformatic tools. The GPCR encoded by the sequences described herein has been termed PFI-019.

[0035] The term "nucleotide sequence" as used herein refers to an oligonucleotide sequence or polynucleotide sequence, and variants, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be DNA or RNA of genomic or synthetic or recombinant origin which may be double-stranded or single-stranded whether representing the sense or antisense strand.

[0036] Preferably, the term "nucleotide sequence" means DNA. More preferably, the term "nucleotide sequence" means DNA prepared by use of recombinant DNA techniques (i.e. recombinant DNA).

[0037] As used herein "amino acid sequence" refers to peptide or protein sequences or portions thereof.

[0038] The present invention does not cover the native PFI-019 when it is in its natural environment and when it has

been expressed by its native nucleotide coding sequence which is also in its natural environment and when that nucleotide sequence is under the control of its native promoter which is also in its natural environment, nor does it cover its native nucleotide coding sequence in its natural environment under the control of its native promoter in its natural environment.

[0039] As used herein "biologically active" refers to a PFI-019 having structural, regulatory or biochemical functions of the naturally occurring PFI-019.

[0040] As used herein, "immunological activity" is defined as the capability of the natural, recombinant or synthetic PFI-019 or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

[0041] The term "antibody" includes polyclonal antibodies, monoclonal antibodies, antibody fragments produced by proteolytic digestion of whole antibody molecules, such as Fab or F(ab')₂ fragments, as well as antibody fragments selected from expression libraries of Fab or single-chain Fv fragments. As the skilled person will be well aware, antibodies can be generated in animals such as mice, rats, rabbits, goats, sheep, etc, by immunising the animal with the polypeptide or oligopeptides selected from the sequence of the polypeptide. If such oligopeptides are used, they are often coupled to carrier proteins - all methods the skilled person will be familiar with.

[0042] Monoclonal antibodies may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique originally described by Koehler and Milstein (1975, *Nature* 256, 495-497), the human B-cell hybridoma technique (Kosbor et al. (1983) *Immunol Today* 4, 72; Cote et al. (1983) *Proc. Natl. Acad. Sci. (USA)* 80, 2026-2030) and the EBV-hybridoma technique (Cole et al. (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R Liss Inc, pp. 77-96). In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison et al. (1984) *Proc. Natl. Acad. Sci. (USA)* 81, 6851-6855; Neuberger et al. (1984) *Nature* 312, 604-608; Takeda et al. (1985) *Nature* 314, 452-454). Alternatively, techniques described for the production of single chain antibodies (US-A-4946779) can be adapted to produce polypeptide-specific single chain antibodies.

[0043] Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi et al. (1989, *Proc. Natl. Acad. Sci. (USA)* Vol 86 p 3833-3837), and Winter G & Milstein C (1991; *Nature* 349 p293-299).

[0044] The term "derivative" as used herein includes chemical modification of a PFI-019.

[0045] As used herein, the terms "isolated" and "purified" refer to molecules, either nucleic acids or polypeptides/proteins, that are removed from their natural environment and isolated or separated from at least one other component with which they are naturally associated. For example, for nucleic acid sequences, the nucleic acid must be separated from at least one of the genes with which it is naturally associated.

[0046] There are many methods for purifying proteins known to the skilled person, which can be applied to purification of the PFI-019 protein. Often a convenient method involves engineering the cDNA to introduce a sequence encoding a peptide tag, e.g. a hexa-His tag or a Flag peptide tag, either at the 5' end just after the ATG initiation codon, or at the C-terminus before the stop codon, so that the expressed protein will be tagged and can be purified e.g. on a Ni²⁺ chelating column if a hexa-His tag is used, or using commercially available anti-Flag peptide antibodies, e.g. for immunoprecipitation or affinity chromatography techniques. Expression vectors engineered to contain such tags are commercially available, and such methods are well known to the skilled person.

[0047] The invention also encompasses purifying and crystallising the polypeptide, optionally followed by elucidating the three-dimensional structure, preferably by X-ray crystallography. The invention also encompasses deriving a homology model of the three-dimensional structure of the polypeptide of the present invention.

[0048] Once the protein is purified, crystals may be obtained with methods similar to those described by Palczewski et al in *Science* 289, 739-745 (2000), and the structure can then be solved by X-ray crystallography as described in this publication, or other biophysical techniques. Alternatively, or additionally, the three-dimensional structure of the polypeptide of the invention can also be modelled by homology modelling, comprising the steps of aligning the sequence of the polypeptide of the invention with the sequence of a similar polypeptide of known structure, preferably rhodopsin, mapping the sequence differences onto the known structure, thereby deriving a model for the three-dimensional structure of the polypeptide of the invention. The three-dimensional structure, derived either by structure determination or by homology modelling, can then be used for designing compounds that may bind to the polypeptide of the invention, or prediction whether compounds will bind to it.

[0049] The terms "variant", "homologue" or "fragment" in relation to the amino acid sequence for the preferred polypeptide of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant polypeptide has PFI-019 activity. In particular, the term "homologue" covers homology with respect to structure and/or function.

[0050] The terms "variant", "homologue" or "fragment" in relation to the nucleotide sequence coding for the preferred polypeptide of the present invention include any substitution of, variation of, modification of, replacement of, deletion

of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for or is capable of coding for a polypeptide having PFI-019 activity. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence codes for or is capable of coding for a receptor having PFI-019 activity. With respect to sequence homology, preferably there is at least 70-75%, more preferably at least 75-80%, more preferably at least 80-85%, more preferably 85-90%, yet more preferably 90-95%, and most preferably greater than 95% identity to the polynucleotide sequence shown in SEQ ID NO: 1.

[0051] In particular, "homology" as used herein can be determined by commercially available computer programs that produce an optimal alignment between two sequences and then calculate % homology (i.e. when comparing protein sequences, also scoring for conservative substitutions, such as a change between Lysine and Arginine, for which the software will use standard scoring matrices) and % identity (i.e. only counting identical residues) between the aligned sequences. Typical examples of such computer programs are GAP and BESTFIT, which are part of the GCG suite of programs (Devereux et al (1984) Nucl. Acids Res. 12, 387; Wisconsin Package Version 10, Genetics Computer Group, Madison, Wisconsin), or ClustalW (Thompson, J.D. et al (1994) Nucl. Acids Res. 22, 4673-80) which can also be used for multiple sequence alignments.

[0052] As used herein, the terms "variant", "homologue", "fragment" and "derivative" also include allelic variations of the sequences.

[0053] The term "variant" also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences presented herein. Preferably, the term "variant" encompasses sequences that are complementary to sequences that are capable of hybridising under conditions of medium to high stringency (e.g. 55-65°C and 0.1xSSC {1xSSC = 0.15 M NaCl, 0.015 M Na₃ citrate pH 7.0}) to the nucleotide sequences presented herein.

[0054] The present invention also covers nucleotide sequences that can hybridise to the nucleotide sequences of the present invention (including complementary sequences of those presented herein). In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention under conditions of medium to high stringency (e.g. 55-65°C and 0.1xSSC). Such polynucleotides or oligonucleotides may be used as probes, or for amplifying all or part of the sequence of the invention when used as PCR primer. These sequences may also be used to modulate the expression of PFI-019 through antisense techniques or the use of ribozymes. Antisense nucleic acids, preferably oligonucleotide about 10 to 30 bases long, capable of specifically binding to the PFI-019 mRNA transcript, i.e. complementary to the sequence in SEQ ID NO 1, are introduced into cells by standard techniques (e.g. using liposomes), bind to the target nucleotide sequences in the cells and thereby prevents transcription and/or translation of the target sequence. The antisense oligonucleotides are often made more stable by modifications such as using phosphorothioate or methylphosphonate oligonucleotides.

[0055] Antisense sequences can also be incorporated into ribozymes such as hammerhead or hairpin ribozymes. These can also be introduced into cells and are thought to cleave the specific transcripts and thereby prevent their translation. Such ribozymes can be introduced into cells by gene therapy approaches, or by standard techniques, e.g. using viral vectors or liposomes. They may also be modified chemically to increase their stability to nuclease digestion.

[0056] Details about antisense and ribozyme technologies can be found in textbooks such as I. Gibson (Ed.) Antisense and Ribozyme Methodology, Chapman & Hall; R. Schlingensiepen (1997) Antisense - From Technology to Therapy: Lab Manual and Textbook, Blackwell Science Inc.; P.C. Turner (Ed.) (1997) Ribozyme Protocols, Humana Press.

[0057] The term "vector" includes expression vectors and transformation vectors. The term "expression vector" means a construct capable of *in vivo* or *in vitro* expression. The term "transformation vector" means a construct capable of being transferred from one species to another.

[0058] The term "purinoceptor ligand" refers to a known ligand of the family of purinoceptors such as P2Y₁ receptors. Examples of such ligands include 2-chloro-ATP, 2-methyl-thio-ATP or 2-methyl-thio-ADP.

[0059] Methods how to obtain transgenic animals can be found in I.J. Jackson, C.M. Abbott (Eds) (2000) Mouse Genetics and Transgenics: A Practical Approach, Oxford University Press, and in M.J. Tymms & I. Kola (Eds) (2001) Gene Knockout Protocols (Methods in Molecular Biology, Vol 158), Humana Press.

[0060] Methods for gene therapy approaches are covered in T.F. Kresina (2000) An Introduction to Molecular Medicine and Gene Therapy, John Wiley & Sons, and in T. Friedmann (Ed.) (1998) The Development of Human Gene Therapy (Cold Spring Harbor Monograph Series, 36), Cold Spring Harbor Laboratory.

[0061] For human use, the compounds of the invention, and their pharmaceutically acceptable salts, can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

[0062] For example, the compounds, and their pharmaceutically acceptable salts, can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.

[0063] The compounds can also be administered parenterally, for example, intravenously, intraarterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously,

or they may be administered by infusion or needleless injection techniques. For such parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

DEPOSITS

[0064] The following sample was deposited in accordance with the Budapest Treaty at the recognised depositary The National Collections of Industrial, Food and Marine Bacteria Limited (NCIMB) at 23 St. Machar Drive, Aberdeen, Scotland, AB24 3RY, United Kingdom on 10 April 2001:

[0065] NCIMB number NCIMB 41101 is *Escherichia coli* Pfi-019.

[0066] The depositor was Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom.

[0067] One skilled in the art could readily grow the above-mentioned *E. coli* clone (NCIMB 41101) in Luria Broth containing ampicillin and isolate the plasmid DNA of the clone using the alkali lysis method as described in Sambrook, *et al.*, eds. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, NY, USA. The dideoxy termination method as described by Sanger *et al.* (Proc. Natl Acad Sci (USA) (1977), 74, 5463-5467) and modified by Applied Biosystems (see Applied Biosystems manufacturer's literature) for fluorescent detection could then be used to sequence the DNA and identify PFI-019.

[0068] The present invention also encompasses sequences derivable and/or expressible from that deposit and embodiments comprising the same. The present invention also encompasses partial sequences derivable and/or expressible from that deposit and embodiments comprising the same, wherein those partial sequences code for active polypeptides. The present invention also encompasses proteins comprising sequences derivable and/or expressible from that deposit and embodiments comprising the same. The present invention also encompasses proteins comprising partial sequences derivable and/or expressible from that deposit and embodiments comprising the same, wherein those partial sequences code for active polypeptides.

EXAMPLES

[0069] The present invention will now be described, by way of example only, with reference to the accompanying Figures and Sequence Listing in which:-

Figure 1 shows a flow diagram illustrating the bioinformatics analysis for the sequence of PFI-019.

Figure 2 shows a ClustalW alignment of PFI-019 with the P2Y purinoceptor 1 (P2Y1).

Figure 3 shows the results of a functional, cell-based assay, showing the stimulation of PFI-019 by 2-chloro-ATP, using a FLIPR® technology.

Figure 4 shows the stimulation of PFI-019 by 2-methyl-thio-ATP.

Figure 5 shows the stimulation of PFI-019 by 2-methyl-thio-ADP.

Figure 6 shows the stimulation of PFI-019 by UTP.

SEQ ID NO: 1 shows the nucleotide sequence coding for PFI-019.

SEQ ID NO: 2 shows the corresponding amino acid sequence coding for PFI-019.

SEQ ID NOS: 3 and 4 show the PCR primers used in the Examples.

Example 1: The identification of PFI-019

[0070] PFI-019 was identified in the Incyte database by searching the sequences with known members of the G-protein coupled receptor (GPCR) family using the BLAST algorithm. In order to confirm that PFI-019 was a member of the GPCR family, a number of bioinformatics approaches were performed, as shown in Fig. 1.

(a) BLAST Search against Swissprot

[0071] PFI-019 was searched against Swissprot using the BLAST algorithm (Basic Local Alignment Search Tool (Altschul SF (1993) J. Mol. Evol. 36:290-300; Altschul, SF *et al* (1990) J. Mol. Biol. 215:403-410) to identify the closest protein match. In this case the top hit was to Swissprot accession number P47900, P2Y purinoceptor 1 (P2Y1).

[0072] These results indicate that PFI-019 is a member of the GPCR family.

(b) ClustalW Alignment of PFI-019 with the P2Y purin receptor 1 (P2Y1)

[0073] These results are shown in Figure 2. A star (*) underneath the sequence comparison indicates identical residues in both sequences; a colon (:) indicates a conservative difference between the two sequences (e.g. an Arginine residue in one sequence, with the second sequence having a Lysine in the corresponding position); a point (.) underneath indicates that both sequences have similar amino acids in this position (e.g. an Alanine in one, a Valine in the second sequence). The assignment of these symbols is performed by the software according to scoring matrices such as Blosum62, well known to the skilled person.

(c) BLAST search against a non-redundant human GPCR database

[0074] PFI-019 was searched against a non-redundant human GPCR database comprising mainly sequences from Genbank and Derwent Geneseq databases in order to identify the class of potential agonists for this receptor. The top ten hits are shown below:

		e-value
P2Y purinoceptor 1 (P2Y1) [L:373]	223	2e-59
Uridine nucleotide receptor (UNR) [L:...	203	3e-53
P2U purinoceptor 2 (P2U2) (geneseq) [L:...	187	2e-48
P2U purinoceptor 1 (P2U1) [L:377]	187	2e-48
Cysteinyl Leukotriene receptor CysLT2 (P...	185	7e-48
P2Y purinoceptor 6 (P2Y6) [L:328]	158	8e-40
G protein-coupled receptor GPR17 [L:339]	155	9e-39
CCR9 [receptor for CCL25 (TECK)] [L:...	151	1e-37
G-protein-coupled receptor (celera)...	150	3e-37
Thrombin receptor [L:425]	150	3e-37
(e value = statistical likelihood of the hit occurring by chance)		

[0075] These results demonstrate that PFI-019 is most similar to P2Y receptors and they suggest that PFI-019 encodes a novel GPCR whose ligand is likely to be a nucleotide or a nucleotide derivative.

[0076] It will be appreciated that the foregoing is provided by way of example only and modification of detail may be made without departing from the scope of the invention.

Example 2: Isolation of PFI-019

[0077] Utilising PFI-019 gene specific primers (PFI-019 forward and PFI-019 reverse; SEQ ID NOs: 3 and 4, respectively), these were employed in a PCR to amplify the PFI-019 coding region from human genomic DNA (Boehringer Mannheim), where the conditions were as follows:-

PCR mix:**[0078]**

PFI-019 primers	1 µl (10 µM stock)
Human genomic DNA	2 µl (400ng)
dNTPs (concentration as per kit)	1 µl
platinum Taq high fidelity Polymerase (LTI, Inc.)	0.5 µl
10x amplification Buffer (from PCR kit)	5 µl
MgSO ₄	1.5 µl
dH ₂ O	39 µl

PCR primers:

[0079] Forward Primer (= PFI-019 forward); SEQ ID NO: 3:

5'- ACC ATG AAT GAG CCA CTA GAC TAT TTA GCA AAT-3' (SEQ ID NO: 3)

[0080] Reverse Primer (= PFI-019 reverse); SEQ ID NO: 4:

5'- TCA AGG GTT GTT TGA GTA ACT AAT TTT CTT -3' (SEQ ID NO: 4)

PCR cycle:

[0081]

(1) 94°C 2 mins

(2) 94°C 30 seconds

(3) 54°C 30 seconds

(4) 68°C 2 mins

Steps (2) through to (4) were repeated for a further 27 cycles.

(5) 68°C 15 mins

(6) 4°C soak.

[0082] The PFI-019 PCR product was TOPO cloned (Invitrogen TOPO cloning methodology) into the vector pcDNA4.1/His-Max-TOPO (Invitrogen), according to the manufacturer's instructions. The resulting insert was subsequently sequence-verified on both strands using ABI DNA sequencing methodology as per the manufacturer's protocol.

Example 3: Tissue distribution of PFI-019

[0083] Electronic northern (i.e. analysis of EST sequences in databases) identifies an EST comprising PFI-019 DNA sequence in a colon cDNA library.

Example 4: Functional cell-based assays for agonist activation of PFI-019

[0084] Fluorescence Imaging Plate Reader (FLIPR®) technology was employed as a means to detect activation of PFI-019 by agonists in a cell-based assay.

[0085] 5 x 10⁶ Human Embryonic Kidney (HEK) 293 cells expressing the mouse Gα15 gene (from here on called '293 cells'), were transiently transfected with 7.5 µg of PFI-019 (contained within the pcDNA4HIS-max-TOPO (Invitrogen) plasmid) vector, or vector alone, using Lipofectamine Plus® reagent (Gibco BRL) as per the manufacturer's protocol. The plasmid pcDNA4HIS-max-TOPO was used as it contains elements that up-regulate the level of gene transcription over standard pcDNA3.1 vectors. 24 hrs post-transfection, the cells were detached from the flask using Trypsin/EDTA solution (LTI) and seeded into a black sided, Poly-D-lysine-treated, 96-well plate (Becton Dickinson) at 5 x 10⁴ cells/well density. The plates were left overnight to allow the cells to adhere to the bottom of the wells. The medium was removed from the cells and replaced with 100 µl warm (37°C) dye loading solution (50 µg Fluo3 (Molecular Probes) in 20 µl DMSO + 20% pluronic acid in DMSO, added to 11 ml Dulbecco's Modified Eagles Medium containing 1x Probenecid (100x Probenecid - 0.71 g Probenecid was dissolved in 5 ml 1M NaOH and 5 ml Dulbeccos' Phosphate Buffered Saline (PBS), per plate; Probenecid (Molecular Probes) inhibits activity of the anion transport protein, thus improving dye loading). The plates were then incubated for 1 hr at 37°C. Plates were subsequently washed with 250 µl of wash buffer per well (5 ml 100x Probenecid stock + 495 ml PBS, pH 7.4) 4 times. The plates were returned to the 37°C/5%CO₂ incubator for 30 mins prior to processing within the FLIPR® instrument. The FLIPR® processing involved reading the fluorescence for all samples for 2 minutes; during this time the fluorescence baseline was determined for the first 10 seconds. The desired amount of compound was then automatically transferred to the wells, and the fluorescence was continuously monitored for the remainder of the time. All compounds were diluted in wash buffer

Analysis of PFI-019 activation by various purinoceptor agonist compounds in a FLIPR® cell-based assay

[0086] Using methodology as described in detail above, purinoceptor agonist compounds were identified as being able to functionally activate PFI-019.

[0087] Figures 3, 4, 5 and 6 show the response of PFI-019-transfected 293 cells to 2-chloroadenosine triphosphate tetrasodium (2-chloro-ATP; Fig. 3), 2-Methylthioadenosine triphosphate tetrasodium (2-methyl-thio-ATP; Fig. 4); 2-Methylthioadenosine diphosphate trisodium (2-methyl-thio-ADP, Fig. 5) and Uridine triphosphate (Fig. 6). The graphs

show fluorescence intensity versus time (in seconds); the black line shows the response to the respective compound by PFI-019-expressing cells, whereas the grey line shows the response by mock-transfected cells. All compounds were purchased from Sigma. Vector-only transfected 293 cells gave no measurable response to these compounds.

Example 5: Engineering of stable cell lines expressing high levels of PFI-019

[0088] A suitable host cell line, e.g. HEK293 cells or CHO cells (engineered to express a desired G protein such as G α 15), is transfected as described in Example 4, using Lipofectamine or electroporation, with a suitable mammalian cell expression vector containing the cDNA (preferably without any 5' or 3' untranslated regions) encoding PFI-019, and containing a selectable marker, e.g. a neomycin resistance gene. Following transfection, selection pressure is applied, e.g. by adding 400-800 μ g/ml G418 to the growth medium and thereby killing all cells which have not taken up the vector which contains the neomycin resistance gene. After about 3-4 weeks of selection, individual clones are picked and expanded for further analysis. The individual clones can be analysed e.g. by Northern blot, using a labelled probe designed from the PFI-019 cDNA sequence.

Example 6: Ligand binding assays

[0089] Cells expressing PFI-019, either 24-72 hours after transient transfection as described in Example 4, or engineered as described in Example 5, are harvested by scraping, resuspended in 20 ml of ice-cold assay buffer (50 mM Tris-HCl pH 7.4), homogenised, and the resulting suspension is centrifuged at 20,000g, 4°C for 30 minutes. The supernatant is decanted, the pellet resuspended in 3 ml of assay buffer and re-homogenised (50 mM Tris-HCl pH 7.4). The protein concentration is determined via Bradford's assay (Biorad), according to the manufacturer's recommendations.

[0090] Aliquots of this membrane preparation containing 200 μ g protein are then incubated with various potential ligands, such as nucleotides, nucleotide analogues, radiolabeled to high specific activity, for about 2 hrs at room temperature or at 30°C (the optimal conditions, ion concentrations, incubation time and temperature need to be determined for each ligand). To terminate incubations, samples are rapidly filtered using the Brandell cell harvester onto Wallac Filtermats (Perkin Elmer) (which have been previously soaked (for 1h) in a 0.3% (v/v) solution of PEI (polyethylenimine; Sigma) in assay buffer to reduce Filtermat binding). Immediately, the Filtermat/wells are washed four times in rapid succession with 2 ml of assay buffer per well. Filtermats are dried using a microwave oven, and Meltilex scintillant (Perkin Elmer) is melted onto the Filtermats using the Wallac Meltilex heat sealer. The bound radioactivity on the Filtermats is determined using the Wallac betaplate scintillation counter.

[0091] The specific binding is defined as the difference between total radioactivity bound minus the radioactivity measured in the presence of an excess of unlabelled ligand. Mock-transfected cells are also measured to assess whether the host cells express receptors for the ligands used endogenously.

Example 7: β -lactamase assay

[0092] A CHO cell line engineered to stably contain cyclic AMP response elements (CRE) functionally linked to the coding region of reporter gene β -lactamase as well as the nuclear factor of activated T-cell promoter NF-AT (Flanagan et al (1991) Nature 352, 803-807) linked to the coding region of reporter gene β -lactamase (CHO-CRE-NFAT-BLA) is transfected stably as described in Example 5, with a plasmid containing the cDNA encoding PFI-019 functionally linked to a promoter that drives expression in mammalian cells, e.g. pcDNA3.1, and selected for stable expression of PFI-019.

[0093] The CHO-CRE-NFAT-BLA cells expressing PFI-019 are then seeded at 4×10^3 cells per well in 96-well plates, and incubated for 60 hours at 37°C in a CO₂ incubator (5% CO₂). The medium is then removed, and 90 μ l starvation medium (DMEM with high glucose, 0.1mM Non-essential amino acids, 1mM sodium pyruvate, 25mM Hepes buffer, without serum or antibiotics) is added to each well, and the cells are incubated overnight. The cells are then stimulated by addition of 10 μ l 2-chloro-ATP or 2-methyl-thio-ATP (or 1 μ M ionomycin for positive control) prepared in DMEM with 1% dialysed fetal bovine serum per well. Following incubation at 37°C/5% CO₂ for 5 hours, 20 μ l of 6x dye solution (CCF2 Loading kit from Aurora, Cat # 00 100 012, contains solutions A-D; to prepare 6x dye solution, 36 μ l solution A (CCF2-AM), 180 μ l solution B, 2.8ml solution C and 225 μ l solution D are mixed according to the instructions) are added per well, and the plate is incubated on a rocking platform in the dark at room temperature for 1 hour (rocking at 40 cycles per minute). The fluorescence is then measured in a Cytofluor 4000 (PerSeptive Biosystems), using an excitation wavelength of 405 nm, and measuring emission at wavelengths of 450 nm and 530 nm.

[0094] When the ligand stimulates the receptor and the response leads to either a change in cAMP concentration or in calcium concentration in the cells, β -lactamase will be expressed in the cells. The dye is composed of a blue (coumarin) and a green (fluorescein) component which are linked by a β -lactam linker group. When excited at 405 nm, fluorescence energy transfer will occur within the uncleaved molecule, and the emission wavelength will be green.

(around 530 nm). When the linker is cleaved by β -lactamase, no energy transfer can occur, and blue fluorescence results, measured at 450 nm. Measuring the ratio of blue to green fluorescence will give an indication of receptor stimulation. The ratio is agonist dose dependent, and can be used to rank agonists for the receptor.

5

10

15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

<110> Pfizer Ltd. (EP(GB) only)
Pfizer Inc. (US, JP, EP except GB)

<120> Novel Polypeptide

<130> PCS10959A BXP

<150> GB 0030854.4

<151> 2000-12-18

<150> GB 0111031.1

<151> 2001-05-04

<160> 4

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1014

<212> DNA

<213> Homo sapiens

<400> 1

```

atgaatgagc cactagacta tttagcaaat gcttctgatt tccccgatta tgcagctgct 60
tttggaattt gcactgatga aaacatccca ctcaagatgc actacctccc tgttatztat 120
ggcattatct tcctcgtggg atttccaggc aatgcagtag tgatatccac ttacattttc 180
aaaatgagac cttggaagag cagcaccatc attatgctga acctggcctg cacagatctg 240
ctgtatctga ccagcctccc ctctctgatt cactactatg ccagtggcga aaactggatc 300
tttgagagatt tcactgtgaa gtttatccgc ttcagcttcc atttcaacct gtatagcagc 360
atcctcttcc tcactgtttt cagcatcttc cgctactgtg tgatcattca cccaatgagc 420
tgcttttcca ttcacaaaac tcgatgtgca gttgtagcct gtgctgtggt gtggatcatt 480
tcactggtag ctgtcattcc gatgaccttc ttgatcacat caaccaacag gaccaacaga 540
tcagcctgtc tcgacctcac cagttcggat gaactcaata ctattaagtg gtacaacctt 600
attttgactg caactacttt ctgcctcccc ttgggtgatag tgacactttg ctataccacg 660
attatccaca ctctgaccca tggactgcaa actgacagct gccttaagca gaaagcacga 720
aggctaacca ttctgctact ccttgcattht tacgtatggt ttttaccctt ccatactctg 780
agggtcattc ggatcgaatc tcgcctgctt tcaatcagtt gttccattga gaatcagatc 840
catgaagctt acatcgcttc tagaccatta gctgctctga acacctttgg taacctgtta 900
ctatatgtgg tggtcagcga caactttcag caggctgtct gctcaacagt gagatgcaaa 960
gtaagcggga accttgagca agcaaagaaa attagttact caaacaaccc ttga 1014

```

<210> 2

<211> 337

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Asn Glu Pro Leu Asp Tyr Leu Ala Asn Ala Ser Asp Phe Pro Asp
1           5           10           15
Tyr Ala Ala Ala Phe Gly Asn Cys Thr Asp Glu Asn Ile Pro Leu Lys
20           25           30
Met His Tyr Leu Pro Val Ile Tyr Gly Ile Ile Phe Leu Val Gly Phe
35           40           45
Pro Gly Asn Ala Val Val Ile Ser Thr Tyr Ile Phe Lys Met Arg Pro
50           55           60
Trp Lys Ser Ser Thr Ile Ile Met Leu Asn Leu Ala Cys Thr Asp Leu
65           70           75           80

```

Leu Tyr Leu Thr Ser Leu Pro Phe Leu Ile His Tyr Tyr Ala Ser Gly
 85 90 95
 5 Glu Asn Trp Ile Phe Gly Asp Phe Met Cys Lys Phe Ile Arg Phe Ser
 100 105 110
 Phe His Phe Asn Leu Tyr Ser Ser Ile Leu Phe Leu Thr Cys Phe Ser
 115 120 125
 Ile Phe Arg Tyr Cys Val Ile Ile His Pro Met Ser Cys Phe Ser Ile
 130 135 140
 10 His Lys Thr Arg Cys Ala Val Val Ala Cys Ala Val Val Trp Ile Ile
 145 150 155 160
 Ser Leu Val Ala Val Ile Pro Met Thr Phe Leu Ile Thr Ser Thr Asn
 165 170 175
 Arg Thr Asn Arg Ser Ala Cys Leu Asp Leu Thr Ser Ser Asp Glu Leu
 180 185 190
 15 Asn Thr Ile Lys Trp Tyr Asn Leu Ile Leu Thr Ala Thr Thr Phe Cys
 195 200 205
 Leu Pro Leu Val Ile Val Thr Leu Cys Tyr Thr Thr Ile Ile His Thr
 210 215 220
 20 Leu Thr His Gly Leu Gln Thr Asp Ser Cys Leu Lys Gln Lys Ala Arg
 225 230 235 240
 Arg Leu Thr Ile Leu Leu Leu Leu Ala Phe Tyr Val Cys Phe Leu Pro
 245 250 255
 Phe His Ile Leu Arg Val Ile Arg Ile Glu Ser Arg Leu Leu Ser Ile
 260 265 270
 25 Ser Cys Ser Ile Glu Asn Gln Ile His Glu Ala Tyr Ile Val Ser Arg
 275 280 285
 Pro Leu Ala Ala Leu Asn Thr Phe Gly Asn Leu Leu Leu Tyr Val Val
 290 295 300
 Val Ser Asp Asn Phe Gln Gln Ala Val Cys Ser Thr Val Arg Cys Lys
 305 310 315 320
 30 Val Ser Gly Asn Leu Glu Gln Ala Lys Lys Ile Ser Tyr Ser Asn Asn
 325 330 335
 Pro

35 <210> 3
 <211> 33
 <212> DNA
 <213> Homo sapiens

40 <400> 3
 accatgaatg agccactaga ctatttagca aat

33

45 <210> 4
 <211> 30
 <212> DNA
 <213> Homo sapiens

50 <400> 4
 tcaagggttg tttgagtaac taattttcctt

30

55

Claims

1. An isolated polynucleotide comprising:

- (a) a polynucleotide encoding the polypeptide shown in SEQ ID NO 2;
- (b) a polynucleotide encoding the polypeptide encoded by the DNA contained in National Collection of Industrial, Food and Marine Bacteria Limited (NCIMB) Deposit No. 41101;
- (c) a polynucleotide comprising a nucleotide sequence of SEQ ID NO 1;
- (d) a polynucleotide comprising a nucleotide sequence that has at least 70-75% identity to the polynucleotide of any one of (a) to (c);
- (e) a polynucleotide comprising a nucleotide sequence which is capable of hybridising to the polynucleotide of any one of (a) to (d); or
- (f) a polynucleotide fragment of the polynucleotide of any one of (a) to (e).

2. The polynucleotide of claim 1 which encodes a G-protein coupled receptor (GPCR).
3. A polynucleotide probe or primer comprising at least 15 contiguous nucleotides of the polynucleotide of claim 1 or claim 2.
4. A vector comprising the polynucleotide of any one of the preceding claims.
5. A host cell transformed or transfected with the vector of claim 4.
6. The host cell of claim 5 which is a mammalian, bacterial or yeast cell.
7. A process for producing a polypeptide or fragment thereof comprising culturing the host cell of claim 5 or claim 6 under conditions sufficient for the expression of said polypeptide or fragment.
8. The process of claim 7, wherein said polypeptide or fragment is expressed at the surface of said cell.
9. Cells produced by the process of claim 7 or claim 8.
10. A membrane preparation of the cells of claim 9.
11. A polypeptide comprising:
 - (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO 1 and variants, fragments, homologues, analogues and derivatives thereof;
 - (b) a polypeptide of SEQ ID NO 2 and variants, fragments, homologues, analogues and derivatives thereof; or
 - (c) a polypeptide encoded by the cDNA of NCIMB Deposit No. 41101 and variants, fragments, homologues, analogues and derivatives of said polypeptide.
12. An antibody against the polypeptide of claim 11.
13. A compound (agonist) which activates the polypeptide of claim 11.
14. A compound (antagonist) which inhibits activation of the polypeptide of claim 11.
15. A method for identifying a compound which binds to the polypeptide of claim 11 comprising:
 - (a) contacting (i) a detectable compound A known to bind to the polypeptide of claim 11, and (ii) a test compound with cells expressing the polypeptide of claim 11 or a membrane preparation of such cells;
 - (b) contacting the same amount of detectable compound A with the same amount of cells expressing the polypeptide of claim 11 or a membrane preparation of such cells under the same conditions as in step (a) but in the absence of test compound;
 - (c) comparing the amount of compound A bound in steps (a) and (b) thereby identifying a test compound that competes with or blocks the binding of compound A to the polypeptide of claim 11.
16. The method of claim 15, whereby compound A is a nucleotide or nucleotide derivative.
17. A method for identifying a compound which binds to and activates the polypeptide of claim 11 comprising:

(a) contacting a compound with cells expressing on the surface thereof the polypeptide of claim 11 or a membrane preparation of said cells, said polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said polypeptide; said contacting being under conditions sufficient to permit binding of compounds to the polypeptide; and
 5 (b) identifying a compound capable of polypeptide binding by detecting the signal produced by said second component.

18. A method for identifying a compound which binds to and inhibits activation of the polypeptide of claim 11 comprising:

10 (a) contacting (i) a detectable first component known to bind to and activate the polypeptide of claim 11 and (ii) a compound with cells expressing on the surface thereof the polypeptide of claim 11, or a membrane preparation of said cells, said polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said polypeptide; said contacting being under conditions sufficient to permit binding of compounds to the polypeptide; and
 15 (b) determining whether the first component binds to the polypeptide by detecting the absence or otherwise of a signal generated from the interaction of the first component with the polypeptide.

19. The compound of claim 13 or claim 14 for use as a pharmaceutical.

20 20. Use of the compound (agonist) of claim 13 in the manufacture of a medicament in the treatment of a patient having need to activate a receptor.

21. Use of the compound (antagonist) of claim 14 in the manufacture of a medicament in the treatment of a patient having need to inhibit a receptor.

25 22. Use of the antibody of claim 12 in the manufacture of a medicament for the treatment of a patient having need to activate or inhibit a receptor.

30 23. Use of the polypeptide of claim 11 in the manufacture of a medicament for the treatment of a patient having need to upregulate a receptor.

24. Cells or animals genetically engineered to overexpress or to underexpress the polypeptide of claim 11.

35 25. Cells or animals genetically engineered to exhibit targeted deletion of the polypeptide of claim 11.

26. A microorganism as deposited under the accession number NCIMB 41101 at the National Collections of Industrial, Food and Marine Bacteria Ltd.

40 27. A method of elucidating the three-dimensional structure of the polypeptide of claim 11, comprising the steps of: (a) purifying the polypeptide; (b) crystallising it, and (c) elucidating the structure, in particular by X-ray crystallography.

45 28. A method of modelling the structure of the polypeptide of claim 11, comprising the steps of: (a) aligning the sequence with a sequence of a protein of known three-dimensional structure, in particular rhodopsin; (b) mapping the detected sequence differences of the polypeptide of claim 11 onto the known structure, (c) deriving a homology model of the polypeptide of claim 11.

Figure 1




Figure 2

ClustalW Alignment of PFI-019 with P2Y purinoceptor 1 (P2Y1)

```

PFI-019  MNEPLDYLA-NASDFPDYA---AAFGN-----CTDENIPLKMHYLPVIYGI
P2Y1     MTEVLWPAVPNGTDA AFLAGPGSSWGNSTVASTAAVSSSFKCALTKTGQFYYPVAVIIL
          *. * . * . * : : * : : : * : :
          :

PFI-019  IFLVGFPNAVVISITYIFKMRPWKSSTIIMNLACTDLLYLTSLPFLIHYYASGENWIFG
P2Y1     VFIIGFLGNSVAIWMFVFHMKPWGSGISVYMFNLALADFLYVLTLPALIFYFYNKTDWIFG
          : : : * * : * : : : : * : : : * : * : : * : :
          :

PFI-019  DFMCKFIRFSFHFNLYSILFLTCFSIFRYCVIIHPMSCFSIHKTRCAVVACAVVWIISL
P2Y1     DAMCKLQRFIFHVNLVYGSILFLTCISAHRYSGVVYPLKSLGRLKKKNAICISVLVWLIVV
          * * : : * * : * : * : * : * : : * : : : * : :
          :

PFI-019  VAVIPMTFLITSTNRTNRS-ACDLTSSDELNTIKWYNLILTATTFCPLVIVTLCYTTI
P2Y1     VAISPILFYSGTGVRKNKTITCYDTTSDEYLRSYFIYSMCTTVAMFCVPLVLILGCYGLI
          * : * : : * : : : * * : : * : * : : * : : : * :
          :

PFI-019  IHTLTHGLQTDSCCLKQKARRLTILLLLAFYVCFLPPHILRVIRIESRLLSIS---CSIEN
P2Y1     VRALIYKDLDNSPLRRKSIYLVIIVLTVFAVSYIPFHVMTMNLRARLDFOTPAMCAFND
          : : * : : * : : : * : : * * : : * : : : : * : :
          :

PFI-019  QIHEAYIVSRPLAALNTFGNLLLYVVVSDNFQQAVCSTVR---CKVSGNLEQ-AKKISYS
P2Y1     RVYATYQVTRGLASLNSCVDPILYFLAGDTFRRRLSRATRKASRRSEANLQSKSEDMTLN
          : : : * : * : * : : : : * : : : : * : : : :
          :

PFI-019  NNP-----
P2Y1     ILPEFKQNGDTSL
          *

```



Figure 3: Stimulation of PFI-019 by 2-chloro-ATP**Figure 4: Stimulation of PFI-019 by 2-methyl-thio-ATP**

Figure 5: Stimulation of PFI-019 by 2-methyl-thio-ADP





Figure 6: Stimulation of PFI-019 by UTP



(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 219 638 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
24.07.2002 Bulletin 2002/30

(51) Int Cl.7: **C07K 14/705, C12N 15/12**

(43) Date of publication A2:
03.07.2002 Bulletin 2002/27

(21) Application number: **01310136.5**

(22) Date of filing: **04.12.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **18.12.2000 GB 0308544**
04.05.2001 GB 1110311

(83) Declaration under Rule 28(4) EPC (expert
solution)

(71) Applicants:
• **Pfizer Limited**
Sandwich, Kent CT13 9NJ (GB)
Designated Contracting States:
GB
• **Pfizer Inc.**
New York, New York 10017 (US)
Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

(72) Inventor: **Fidock, Mark David,**
of Pfizer Global Research and
Sandwich, Kent CT13 9NJ (GB)

(74) Representative: **Hayles, James Richard**
UK Patent Department,
Pfizer Limited,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(54) **G-protein coupled receptors having homology to the P2Y purinoreceptor 1 (P2Y1)**

(57) Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 and variants, fragments, homo-

logues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof.

EP 1 219 638 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 01 31 0136

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	DATABASE EMBL 'Online! EBI; 24 March 2001 (2001-03-24) ABOLA ET AL.: "Homo sapiens chromosome 13 clone RP11-286P8, complete sequence" Database accession no. AC026756 XP002199632 *Version 15. Nucleotides 140188-141201*	1-6,9,11	C07K14/705 C12N15/12
Y	*same citations*	1-12, 15-18, 22-28	
X	-& DATABASE GENE BANK 'Online! NCBI; 30 October 2000 (2000-10-30) ABOLA ET AL.: "Homo sapiens chromosome 13 clone RP11-286P8, WORKING DRAFT SEQUENCE, 2 unordered pieces " Database accession no. AC026756 XP002199633 *Version 12. Nucleotides 153089-154202*	1-6,9,11	
Y	*same citations*	1-12, 15-18, 22-28	

-/--			
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
MUNICH		22 May 2002	Steffen, P
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>			

EPO FORM 1503 03 82 (P04C07)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 01 31 0136

Claim(s) not searched:
13, 14, 19-21

Reason for the limitation of the search:

Present claims 13, 14, 19-21 relate to compounds and uses thereof defined by reference to a desirable characteristic or property, namely, that the compounds are undefined agonists or antagonists of the polypeptide of the application.

The claims cover all compounds and uses thereof having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds and uses. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compounds and uses thereof by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, no search has been carried out for claims 13, 14, 19-21.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 31 0136

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	<p>AYYANATHAN KASIRAJAN ET AL: "Cloning and chromosomal localization of the human P2Y1 purinoceptor." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 218, no. 3, 1996, pages 783-788, XP002199629 ISSN: 0006-291X * page 784; figure 2 *</p>	1-6,9,11	
X	<p>VON KUEGELGEN IVAR ET AL: "Molecular pharmacology of P2Y-receptors." NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 362, no. 4-5, November 2000 (2000-11), pages 310-323, XP002199630 ISSN: 0028-1298 * page 312 - page 315; tables 1,2 * * page 318 - page 319 *</p>	1-11, 15-18	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	<p>*same citations*</p>	1-12, 15-18, 22-28	
Y	<p>GENTLES A J ET AL: "Why are human G-protein-coupled receptors predominantly intronless?" TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 15, no. 2, February 1999 (1999-02), pages 47-49, XP004156924 ISSN: 0168-9525 * page 47, left-hand column, paragraph 1; table 1 *</p>	1-12, 15-18, 22-28	
	---	--- -/--	

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 31 0136

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	<p>LEE D K ET AL: "Cloning and characterization of additional members of the G protein-coupled receptor family" BIOCHIMICA ET BIOPHYSICA ACTA. GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol. 1490, no. 3, 29 February 2000 (2000-02-29), pages 311-323, XP004275600 ISSN: 0167-4781 * the whole document *</p> <p style="text-align: center;">---</p>		
A	<p>MARCHESE ET AL: "Discovery of three novel orphan G-protein-coupled receptors" GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 56, no. 1, 15 February 1999 (1999-02-15), pages 12-21, XP002108432 ISSN: 0888-7543 * the whole document *</p> <p style="text-align: center;">---</p>		<p>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</p>
A	<p>O'DOWD B F ET AL: "Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 187, no. 1, 10 March 1997 (1997-03-10), pages 75-81, XP004093242 ISSN: 0378-1119 * the whole document *</p> <p style="text-align: center;">---</p>		

-/--

EPO FORM 1503 03.82 (P04C10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 01 31 0136

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P, X	WO 01 49847 A (WHITE DAVID ; GLUCKSMANN MARIA ALEXANDRA (US); MILLENNIUM PHARM INC) 12 July 2001 (2001-07-12) *SEQ ID NO's 1 and 2* * figures 1-7 * -----	1-12, 15-18, 22-28	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)

EPO FORM 1503 03.82 (P04C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 31 0136

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

22-05-2002

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0136471	A	25-05-2001	AU	1769601 A	30-05-2001
			WO	0136471 A2	25-05-2001
WO 0187937	A	22-11-2001	AU	6472101 A	26-11-2001
			WO	0187937 A2	22-11-2001
			AU	6181401 A	03-12-2001
			WO	0190359 A2	29-11-2001
WO 0136473	A	25-05-2001	AU	1617801 A	30-05-2001
			WO	0136473 A2	25-05-2001
WO 0149847	A	12-07-2001	AU	2458101 A	16-07-2001
			WO	0149847 A2	12-07-2001

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82